National brain tumour research funding needs to increase to £35 million a year
MHRA clinical trial consultation
The Medicines and Healthcare products Regulatory Agency (MHRA) has launched an eight-week public consultation on proposals for legislative changes for clinical trials.
The MHRA is an executive agency of the Department of Health and Social Care and is responsible for ensuring that medicines and medical devices work and are acceptably safe.
It is consulting on a set of proposals to “improve and strengthen the UK clinical trials legislation” to help “make the UK the best place to research and develop safe and innovative medicines.”
The MHRA believes that this consultation is an opportunity to improve regulations to support clinical trials in the best interests of patients, in line with the ambitions of the Life Sciences Vision, to make the UK the leading global centre for innovative research design and delivery, across all types and phases of trials.
The overall aim is to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials.
If you would like to find out more and possibly help shape the future legislation for clinical trials, click here.
This consultation is open now until 14th March 2022.
If you found this story interesting or helpful, sign up to our weekly e-news and keep up to date with all the latest from Brain Tumour Research.